367 related articles for article (PubMed ID: 23756181)
1. Protein tyrosine phosphatases as novel targets in breast cancer therapy.
Nunes-Xavier CE; Martín-Pérez J; Elson A; Pulido R
Biochim Biophys Acta; 2013 Dec; 1836(2):211-26. PubMed ID: 23756181
[TBL] [Abstract][Full Text] [Related]
2. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
Kim M; Baek M; Kim DJ
Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
[TBL] [Abstract][Full Text] [Related]
3. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
[TBL] [Abstract][Full Text] [Related]
5. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
6. A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy.
Celtikci B
Adv Exp Med Biol; 2021; 1275():357-382. PubMed ID: 33539023
[TBL] [Abstract][Full Text] [Related]
7. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.
Kaltenmeier CT; Vollmer LL; Vernetti LA; Caprio L; Davis K; Korotchenko VN; Day BW; Tsang M; Hulkower KI; Lotze MT; Vogt A
J Pharmacol Exp Ther; 2017 Apr; 361(1):39-50. PubMed ID: 28154014
[TBL] [Abstract][Full Text] [Related]
8. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets.
Khan S; Shukla S; Sinha S; Meeran SM
Cytokine Growth Factor Rev; 2013 Dec; 24(6):503-13. PubMed ID: 24210902
[TBL] [Abstract][Full Text] [Related]
9. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
10. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
11. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities.
Hendriks WJ; Pulido R
Biochim Biophys Acta; 2013 Oct; 1832(10):1673-96. PubMed ID: 23707412
[TBL] [Abstract][Full Text] [Related]
15. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells.
Boerner JL; Gibson MA; Fox EM; Posner ED; Parsons SJ; Silva CM; Shupnik MA
Mol Endocrinol; 2005 Nov; 19(11):2660-70. PubMed ID: 15976008
[TBL] [Abstract][Full Text] [Related]
16. SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF.
Wang B; Lemay S; Tsai S; Veillette A
Mol Cell Biol; 2001 Feb; 21(4):1077-88. PubMed ID: 11158295
[TBL] [Abstract][Full Text] [Related]
17. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
18. Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
Dempke WCM; Uciechowski P; Fenchel K; Chevassut T
Oncology; 2018; 95(5):257-269. PubMed ID: 29925063
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
20. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Carmi C; Mor M; Petronini PG; Alfieri RR
Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
